OEP fits into this positive narrative, as mgmt is happy with progress thus far, seeing continued strength as the selling season progresses."Wieland’s bullish outlook is also supported by his Overweight (i.e. Buy) rating and $29 price target, which implies a 132% one-year upside.
The stock has a Strong Buy consensus rating, based on 3 Buy reviews and 1 Hold.
Shares are selling for $12.50 and the average price target, at $17.67, suggests room for a 41% upside in the next 12 months.
(See BNFT stock analysis on TipRanks)Momo, Inc.
We believe it could lead to a healthier long-term prosperity for a social app,” Chiang noted.Chiang sets a $25 price target here, indicating a possible 68% upside potential, to go along with his Buy rating.
The stock’s average price target of $21.49 suggests a 45% upside from the current share price of $14.83.
(See MOMO stock analysis on TipRanks)To find good ideas for beaten-down stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts.
In addition, they have high dividend yields well above the S&P 500 average, as well as reasonable valuations that could provide investors with high total returns in the years ahead.Undervalued Dividend Aristocrat 1: AbbVieAbbVie Inc.
AbbVie was spun off from Abbott Laboratories (ABT), its former parent company which is also a Dividend Aristocrat.
The company also raised full-year guidance and now expects 2020 adjusted earnings-per-share in a range of $10.47 to $10.49, which would make for another year of growth.AbbVie also raised its dividend by 10% in late October.
The stock has a high dividend yield of 5.3%, making it an attractive mix of yield and growth.
For example, AbbVie has seen strong growth from Imbruvica, which saw a 9% increase in sales last quarter.
This means that if AbbVie's valuation expanded from 8.4 to 10.5 over the next five years, total returns (including EPS growth and dividends) could exceed 10% per year.Undervalued Dividend Aristocrat 2: Walgreens Boots AllianceWalgreens Boots Alliance (NYSE: WBA) is a major pharmacy retailer with nearly 19,000 stores in 11 countries.
The company anticipates a recovery in the upcoming year, with fiscal 2021 guidance that calls for low single-digit growth in adjusted EPS.Continuing to grow sales and earnings, albeit at a modest rate, would still allow Walgreens to increase its dividend each year, as it has done for 45 consecutive years.
With a forward P/E ratio of 7.9 compared with our fair value estimate of 10, we believe Walgreens stock can provide total returns of 13%-14% per year over the next five years.Undervalued Dividend Aristocrat 3: AT&TAT&T Inc (NYSE: T) is a telecommunications giant with a large offering of services including wireless, broadband, and pay TV.
The company has invested heavily to restore growth in recent years, including the massive ~$85 billion acquisition of Time Warner, which owns multiple valuable media properties including HBO, CNN, and the Warner Bros.
This is crucial for AT&T's ability to pay its dividend, which is presumably the biggest reason to own the stock.
AT&T currently yields 7.3%, an extremely high yield considering the S&P 500 average yield is under 2%.
Plus, AT&T has increased its dividend for over 30 years in a row.The stock is also significantly undervalued in our view, trading at a forward P/E ratio of 8.9 compared with our fair value estimate of 11.
Including the 7.3% dividend yield and 3% expected annual earnings-per-share growth, expected returns could reach nearly 15% over the next five years.See more from Benzinga * Click here for options trades from Benzinga * Analysts React To Gap's Earnings Miss, 20% Fall: Near-Term Visibility Diminished * 50 Stocks Moving In Wednesday's Mid-Day Session(C) 2020 Benzinga.com.
LendingTree is based in North Carolina, with offices in New York, Chicago, and Seattle.In the third quarter, the company showed mixed fiscal results.
Tandon noted, “[We] remain positive on the shares of TREE LT as we believe that the company is well-positioned to generate strong and consistent revenue… Consumer revenue dropped 68% Y/Y as the pandemic constrained consumer credit originations, but trends improved on a sequential basis due to better personal loan volumes and a seasonal boost from the student loan business…""TREE's diversified portfolio of personal finance products and the strong secular trends driving the shift of personal finance advertising and shopping to digital channels will help the company achieve its LT growth targets,” the analyst concluded.
To this end, Tandon rates TREE a Buy, and sets a $375 price target.
At current levels, his target suggests a 44% upside for the stock in 2021.
The stock’s average price target, $362, implies it has room for 39% growth from the current share price of $260.09.
(See TREE stock analysis on TipRanks)Allegro MicroSystems (ALGM)Allegro MicroSystems is a semiconductor company and fabless manufacturer of integrated circuits for sensor systems and analyst power technologies.
The stock debuted at $14 per share, and the company put 25 million shares up for offer.
Allegro's xMR sensors and power ICs drive technology platform leadership and enable better performance, accuracy, and control for the growing EV market and Industry 4.0 - key for next-generation electrified automotive powertrains, data centers, and factory automation,” Rakesh wrote.Along with his upbeat comments, Rakesh gives this stock a Buy rating and a $28 price target.
His target implies an upside potential of ~17% for the next 12 months.
With a return potential of ~18%, the stock's consensus target price stands at $28.29.
(See ALGM stock analysis on TipRanks)American Well (AMWL)American Well, also called AmWell, connects patients, health care providers, and insurers to promote quality care outcomes in a digital world.
In its first quarter trading as a public company, AmWell reported several gains in key metrics.
The active provider total – more than 62,000 – represents a 930% increase in the past year, and shows strong growth for the company.
And the company registered over 1.4 million patient visits during the quarter, a 450% increase from the year-ago quarter.Piper Sandler’s 5-star analyst Sean Wieland notes the importance of network growth for AMWL, writing in his note on the stock: “62K providers are using the AMWL Network, up almost 10x from a year ago.
The increase was driven primarily by providers employed by, or affiliated with, AMWL's health systems and payor clients… As the number of providers on the network grows, so does the value of the network; network expansion makes it easier for patients to find the right provider and for providers to find the right patient.”Wieland rates AMWL an Overweight (i.e. Buy), and his $44 price target indicates his confidence in an upside of 78% for the next 12 months.
The shares are selling for $24.71 and their average price target, at $35.86, represents a 45% upside potential.
(See AMWL stock analysis at TipRanks)To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts.
6 hours ago
6 hours ago
7 hours ago
7 hours ago
Get monthly updates and free resources.
CONNECT WITH US